A 62-year-old Indian man presents with a 3-month history of progressive bone pain in the lumbar spine and right hip. He reports fatigue and recurrent infections over the past 2 months. On examination, he is pale and has mild hepatomegaly. Laboratory investigations reveal: Hemoglobin 8.2 g/dL, serum creatinine 2.8 mg/dL, serum calcium 11.8 mg/dL (corrected), and serum albumin 2.1 g/dL. Serum protein electrophoresis shows an M-spike of 4.2 g/dL in the gamma region. Bone marrow aspirate shows 45% plasma cells. X-ray spine reveals multiple lytic lesions. Which of the following is the most appropriate next step in confirming the diagnosis and assessing disease burden?

Explanation

## Diagnostic Confirmation and Disease Characterization in Multiple Myeloma ### Clinical Context This patient presents with the classic **CRAB criteria** of multiple myeloma: - **C**alcium elevation (11.8 mg/dL) - **R**enal impairment (creatinine 2.8 mg/dL) - **A**nemia (Hb 8.2 g/dL) - **B**one lesions (multiple lytic lesions on X-ray) Additionally: M-spike of 4.2 g/dL on SPEP and 45% plasma cells on bone marrow aspirate. The diagnosis is strongly suspected; the **next step** is to characterize the monoclonal protein precisely and assess the free light chain ratio. ### Why Immunofixation Electrophoresis (IFE) + Serum Free Light Chain (sFLC) Assay? **Key Point:** SPEP detects an M-spike but **cannot identify the immunoglobulin class or light chain type**. Immunofixation electrophoresis (IFE) is the **gold standard** for characterizing the specific monoclonal protein (IgG, IgA, IgD, IgE, or free light chain only) and is **mandatory** per IMWG diagnostic criteria (Rajkumar et al., *Lancet Oncology*, 2014). **High-Yield:** The serum free light chain (sFLC) assay: - Detects **light-chain-only myeloma** (10–15% of cases where SPEP may be negative) - Provides the **involved/uninvolved FLC ratio** — an independent prognostic marker - An **sFLC ratio >100** (with involved FLC ≥100 mg/L) is itself a **myeloma-defining event** (MDE) per IMWG 2014 criteria, even without CRAB features - Is essential for **MRD monitoring** during and after treatment Together, IFE + sFLC fulfill the requirement of **confirming diagnosis** (protein characterization) and **assessing disease burden** (FLC ratio as prognostic marker). ### Why Not the Other Options? | Option | Limitation | |---|---| | **A) Repeat BM biopsy + cytogenetics** | BM already shows 45% plasma cells — diagnosis is established; cytogenetics (FISH) is important but is a **second-line** step after protein characterization | | **C) PET-CT** | Useful for extramedullary disease and skeletal survey, but **not the next confirmatory step**; lytic lesions are already demonstrated on plain X-ray | | **D) Beta-2 microglobulin + LDH** | Important for **ISS/R-ISS staging and prognosis**, but these do **not confirm diagnosis** or characterize the monoclonal protein | ### NEET PG High-Yield Sequence (IMWG Guidelines) 1. **Confirm & characterize:** SPEP → **IFE + sFLC** (mandatory baseline) 2. **Staging:** Beta-2 microglobulin, albumin, LDH (ISS / R-ISS) 3. **Cytogenetics:** FISH for del(17p), t(4;14), t(14;16) — high-risk stratification 4. **Imaging:** Whole-body low-dose CT or PET-CT (preferred over plain X-rays per updated guidelines) **Clinical Pearl:** Per IMWG 2014 diagnostic criteria (referenced in Harrison's Principles of Internal Medicine, 21st ed.), IFE is **required** to confirm the presence and type of monoclonal protein. SPEP alone is insufficient for diagnosis confirmation. The sFLC ratio >100 is a standalone myeloma-defining event. **Mnemonic:** **IFE first** = **I**dentify the **F**ree light chain and **E**lectrophoresis type before staging or imaging.